Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Decrease in Short Interest

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 56,900 shares, a decrease of 34.9% from the August 15th total of 87,400 shares. Based on an average daily trading volume, of 61,400 shares, the short-interest ratio is currently 0.9 days. Approximately 1.8% of the shares of the company are sold short.

Institutional Trading of Vivos Therapeutics

A hedge fund recently bought a new stake in Vivos Therapeutics stock. Armistice Capital LLC acquired a new stake in Vivos Therapeutics, Inc. (NASDAQ:VVOS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 57,000 shares of the company’s stock, valued at approximately $709,000. Armistice Capital LLC owned about 4.29% of Vivos Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 26.35% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets lifted their price target on Vivos Therapeutics from $6.40 to $6.60 and gave the company a “buy” rating in a research note on Tuesday, August 20th.

Vivos Therapeutics Stock Up 3.1 %

Shares of NASDAQ VVOS opened at $2.95 on Friday. The firm has a 50-day moving average price of $2.54 and a 200 day moving average price of $2.85. Vivos Therapeutics has a 52 week low of $1.91 and a 52 week high of $48.79. The stock has a market capitalization of $9.52 million, a price-to-earnings ratio of -0.27 and a beta of 7.74.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.60) earnings per share (EPS) for the quarter. Vivos Therapeutics had a negative net margin of 85.90% and a negative return on equity of 652.32%. The company had revenue of $4.05 million for the quarter.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.